Therapeutic advances in the treatment of osteoporosis

Bibliography

• MARTIN TJ, SIMS NA: Osteoclast-derived activity in the coupling of bone formation to resorption. Trends Mol. Med. (2005) 11(2):76-81.
   PubMed Web of Science ®Google Scholar
• NATIONAL OSTEOPOROSIS FOUNDATION: America's bone health: the state of osteoporosis and low bone mass in our nation. (2002)
   Google Scholar
• LANE NE: Epidemiology, etiology and diagnosis of osteoporosis. Am. J. Obstet. Gynecol. (2006) 194(2 Suppl.):S3-S11.
   Google Scholar
• CRANNEY A: Treatment of postmenopausal osteoporosis. BMJ (2003) 327(7411):355-356.
   PubMed Web of Science ®Google Scholar
• RIGGS BL, PARFITT AM: Drugs used to treat osteoporosis: the critical need for a uniform nomenclature based on their action on bone remodeling. J. Bone Miner. Res. (2005) 20(2):177-184.
   PubMed Web of Science ®Google Scholar
• HODSMAN AB, BAUER DC, DEMPSTER DW et al.: Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. Endocr. Rev. (2005) 26(5):688-703.
   PubMed Web of Science ®Google Scholar
• CRANNEY A, PAPAIOANNOU A, ZYTARUK N et al.: Parathyroid hormone for the treatment of osteoporosis: a systematic review. CMAJ (2006) 175(1):52-59.
   PubMed Web of Science ®Google Scholar
• RUSSELL RG: Bisphosphonates: from bench to bedside. Ann. N. Y. Acad. Sci. (2006) 1068:367-401.
   PubMed Web of Science ®Google Scholar
• RODAN GA, FLEISCH HA: Bisphosphonates: mechanisms of action. J. Clin. Invest. (1996) 97(12):2692-2696.
   PubMed Web of Science ®Google Scholar
• LUCKMAN SP, HUGHES DE, COXON FP et al.: Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J. Bone Miner. Res. (1998) 13(4):581-589.
   PubMed Web of Science ®Google Scholar
• CRANNEY A, WELLS G, WILLAN A et al.: Meta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women. Endocr. Rev. (2002) 23(4):508-516.
   PubMed Web of Science ®Google Scholar
• CRANNEY A, TUGWELL P, ADACHI J et al.: Meta-analyses of therapies for postmenopausal osteoporosis. III. Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis. Endocr. Rev. (2002) 23(4):517-523.
   PubMed Web of Science ®Google Scholar
• HEFFERNAN MP, SAAG KG, ROBINSON JK, CALLEN JP: Prevention of osteoporosis associated with chronic glucocorticoid therapy. JAMA (2006) 295(11):1300-1303.
   Google Scholar
• CHESNUT III CH, SKAG A, CHRISTIANSEN C et al.: Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J. Bone Miner. Res. (2004) 19(8):1241-1249.
   PubMed Web of Science ®Google Scholar
• GERTZ BJ, HOLLAND SD, KLINE WF et al.: Studies of the oral bioavailability of alendronate. Clin. Pharmacol. Ther. (1995) 58(3):288-298.
   PubMed Web of Science ®Google Scholar
• RECKER R, LIPS P, FELSENBERG D et al.: Alendronate with and without cholecalciferol for osteoporosis: results of a 15-week randomized controlled trial. Curr. Med. Res. Opin. (2006) 22(9):1745-1755.
   PubMed Web of Science ®Google Scholar
• REID IR, BROWN JP, BURCKHARDT P et al.: Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N. Engl. J. Med. (2002) 346(9):653-661.
   PubMed Web of Science ®Google Scholar
• STAKKESTAD JA, BENEVOLENSKAYA LI, STEPAN JJ et al.: Intravenous ibandronate injections given every 3 months: a new treatment option to prevent bone loss in postmenopausal women. Ann. Rheum. Dis. (2003) 62(10):969-975.
   PubMed Web of Science ®Google Scholar
• THIEBAUD D, BURCKHARDT P, KRIEGBAUM H et al.: Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis. Am. J. Med. (1997) 103(4):298-307.
   PubMed Web of Science ®Google Scholar
• BLACK DM BOONEN S, CAULEY J et al.: Effect of once-yearly infusion of zoledronic acid 5 mg on spine and hip fracture reduction in postmenopausal women with osteoporosis: the HORIZON pivotal fracture trial. J. Bone Miner. Res. (2006) 21(Suppl. 1):s1-s530. Abstract 1054.
   Google Scholar
• GUAY DR: Ibandronate, an experimental intravenous bisphosphonate for osteoporosis, bone metastases and hypercalcemia of malignancy. Pharmacotherapy (2006) 26(5):655-673.
   Google Scholar
• ROSSOUW JE, ANDERSON GL, PRENTICE RL et al.: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA (2002) 288(3):321-333.
   PubMed Web of Science ®Google Scholar
• CRANNEY A, TUGWELL P, ZYTARUK N et al.: Meta-analyses of therapies for postmenopausal osteoporosis. IV. Meta-analysis of raloxifene for the prevention and treatment of postmenopausal osteoporosis. Endocr. Rev. (2002) 23(4):524-528.
   PubMed Web of Science ®Google Scholar
• MARGOLIS RN, WIMALAWANSA SJ: Novel targets and therapeutics for bone loss. Ann. N. Y. Acad. Sci. (2006) 1068:402-409.
   PubMedGoogle Scholar
• McCLUNG MR, SIRIS E, CUMMINGS S et al.: Prevention of bone loss in postmenopausal women treated with lasofoxifene compared with raloxifene. Menopause (2006) 13(3):377-386.
   PubMed Web of Science ®Google Scholar
• KOMM BS, KHARODE YP, BODINE PV et al.: Bazedoxifene acetate: a selective estrogen receptor modulator with improved selectivity. Endocrinology (2005) 146(9):3999-4008.
   PubMed Web of Science ®Google Scholar
• PENDLETON A, ARDEN N, DOUGADOS M et al.: EULAR recommendations for the management of knee osteoarthritis: report of a task force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann. Rheum. Dis. (2000) 59(12):936-944.
   PubMed Web of Science ®Google Scholar
• WHYTE MP: The long and the short of bone therapy. N. Engl. J. Med. (2006) 354(8):860-863.
   PubMed Web of Science ®Google Scholar
• McCLUNG MR, LEWIECKI EM, COHEN SB et al.: Denosumab in postmenopausal women with low bone mineral density. N. Engl. J. Med. (2006) 354(8):821-831.
   Google Scholar
• MILLER PD, BILEZIKIAN JP, DEAL C, HARRIS ST, CI RP: Clinical use of teriparatide in the real world: initial insights. Endocr. Pract. (2004) 10(2):139-148.
   PubMedGoogle Scholar
• BODY JJ, GAICH GA, SCHEELE WH et al.: A randomized double-blind trial to compare the efficacy of teriparatide (recombinant human parathyroid hormone [1-34]) with alendronate in postmenopausal women with osteoporosis. J. Clin. Endocrinol. Metab. (2002) 87(10):4528-4535.
   PubMed Web of Science ®Google Scholar
• McCLUNG MR, SAN MJ, MILLER PD et al.: Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass. Arch. Intern. Med. (2005) 165(15):1762-1768.
   PubMed Web of Science ®Google Scholar
• HODSMAN AB, HANLEY DA, ETTINGER MP et al.: Efficacy and safety of human parathyroid hormone (1-84) in increasing bone mineral density in postmenopausal osteoporosis. J. Clin. Endocrinol. Metab (2003) 88(11):5212-5220.
   PubMed Web of Science ®Google Scholar
• BLACK DM, GREENSPAN SL, ENSRUD KE et al.: The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N. Engl. J. Med. (2003) 349(13):1207-1215.
   PubMed Web of Science ®Google Scholar
• ETTINGER M, GREENSPAN S, MARRIOTT T et al.: PTH (1-84) prevents first vertebral fracture in postmenopausal women with osteoporosis. Results from the TOP study. Arthritis Rheum. (2004) 504:103.
   Google Scholar
• FINKELSTEIN JS, HAYES A, HUNZELMAN JL et al.: The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N. Engl. J. Med. (2003) 349(13):1216-1226.
   PubMed Web of Science ®Google Scholar
• BLACK DM, GREENSPAN SL, ENSRUD KE et al.: The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N. Engl. J. Med. (2003) 349(13):1207-1215.
   PubMed Web of Science ®Google Scholar
• HODSMAN AB, FRAHER LJ, WATSON PH et al.: A randomized controlled trial to compare the efficacy of cyclical parathyroid hormone versus cyclical parathyroid hormone and sequential calcitonin to improve bone mass in postmenopausal women with osteoporosis. J. Clin. Endocrinol. Metab. (1997) 82(2):620-628.
   Google Scholar
• MATSUMOTO T, SHIRAKI M, HAGINO H, IINUMA H, NAKAMURA T: Daily nasal spray of hPTH(1-34) for 3 months increases bone mass in osteoporotic subjects: a pilot study. Osteoporos. Int. (2006) 17(10):1532-1538.
   PubMed Web of Science ®Google Scholar
• MARIE PJ: Strontium ranelate: a physiological approach for optimizing bone formation and resorption. Bone (2006) 38(2 Suppl. 1):S10-S14.
   Google Scholar
• TAKAHASHI N, SASAKI T, TSOUDEROS Y, SUDA T: S 12911-2 inhibits osteoclastic bone resorption in vitro. J. Bone Miner. Res. (2003) 18(6):1082-1087.
   PubMed Web of Science ®Google Scholar
• BARON R, TSOUDEROS Y: In vitro effects of S12911-2 on osteoclast function and bone marrow macrophage differentiation. Eur. J. Pharmacol. (2002) 450(1):11-17.
   PubMedGoogle Scholar
• CANALIS E, HOTT M, DELOFFRE P, TSOUDEROS Y, MARIE PJ: The divalent strontium salt S12911 enhances bone cell replication and bone formation in vitro. Bone (1996) 18(6):517-523.
   PubMed Web of Science ®Google Scholar
• COULOMBE J, FAURE H, ROBIN B, RUAT M: In vitro effects of strontium ranelate on the extracellular calcium-sensing receptor. Biochem. Biophys. Res. Commun. (2004) 323(4):1184-1190.
   PubMed Web of Science ®Google Scholar
• MARIE PJ, HOTT M, MODROWSKI D et al.: An uncoupling agent containing strontium prevents bone loss by depressing bone resorption and maintaining bone formation in estrogen-deficient rats. J. Bone Miner. Res. (1993) 8(5):607-615.
   PubMed Web of Science ®Google Scholar
• GRYNPAS MD, MARIE PJ: Effects of low doses of strontium on bone quality and quantity in rats. Bone (1990) 11(5):313-319.
   PubMed Web of Science ®Google Scholar
• DELANNOY P, BAZOT D, MARIE PJ: Long-term treatment with strontium ranelate increases vertebral bone mass without deleterious effect in mice. Metabolism (2002) 51(7):906-911.
   PubMed Web of Science ®Google Scholar
• GRYNPAS MD, HAMILTON E, CHEUNG R et al.: Strontium increases vertebral bone volume in rats at a low dose that does not induce detectable mineralization defect. Bone (1996) 18(3):253-259.
   PubMed Web of Science ®Google Scholar
• HOTT M, DELOFFRE P, TSOUDEROS Y, MARIE PJ: S12911-2 reduces bone loss induced by short-term immobilization in rats. Bone (2003) 33(1):115-123.
   PubMed Web of Science ®Google Scholar
• AMMANN P, SHEN V, ROBIN B et al.: Strontium ranelate improves bone resistance by increasing bone mass and improving architecture in intact female rats. J. Bone Miner. Res. (2004) 19(12):2012-2020.
   PubMed Web of Science ®Google Scholar
• MEUNIER PJ, ROUX C, SEEMAN E et al.: The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N. Engl. J. Med. (2004) 350(5):459-468.
   PubMed Web of Science ®Google Scholar
• REGINSTER JY, SEEMAN E, DE VERNEJOUL MC et al.: Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J. Clin. Endocrinol. Metab. (2005) 90(5):2816-2822.
   PubMed Web of Science ®Google Scholar
• MATHOO JM, CRANNEY A, PAPAIOANNOU A, ADACHI JD: Rational use of oral bisphosphonates for the treatment of osteoporosis. Curr. Osteoporos. Rep. (2004) 2(1):17-23.
   Google Scholar
• REGINSTER J-Y, MEUNIER PJ, ROUX C, COMPSTON J, ORTOLANI S: Stontium ranelate: an anti-osteoporotic treatment demonstrated vertebral and nonvertebral antifracture efficacy over 5 years in postmenopausal osteoporotic women. Osteoporos. Int. (2006) 17(Suppl. 1):S11.
   Google Scholar
• AREY BJ, SEETHALA R, MA Z et al.: A novel calcium-sensing receptor antagonist transiently stimulates parathyroid hormone secretion in vivo. Endocrinology (2005) 146(4):2015-2022.
   Google Scholar
• CAPPARELLI C, MORONY S, WARMINGTON K et al.: Sclerostin monoclonal antibody treatment of osteoporotic rats completely reverses 1 year of ovariectomy-induced systemic bone loss. J. Bone Miner. Res. (2005) 20(Suppl. 1.):S22-S1082.
   Google Scholar
• MURPHY MG, CERCHIO K, STOCH SA et al.: Effect of L-000845704, an αVβ3 integrin antagonist, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women. J. Clin. Endocrinol. Metab. (2005) 90(4):2022-2028.
   Google Scholar
• MISSBACH M, ALTMANN E, BETSCHART C et al.: AAE581, a potent and highly specific cathepsin K inhibitor, prevents bone resorption after oral treatment in rat and monkey. J. Bone Miner. Res. (2005) 20(Suppl. 1):S251-S252.
   Google Scholar
• ROY SK, PILLAI G, WOODWORTH TG: Safety, effects on markers of bone resorption and pharmacokinetics of cathepsin K inhibitor, aae581, in healthy subjects. J. Bone Miner. Res. (2005) 20(Suppl. 1):S293.
   Google Scholar